JP2020517668A5 - - Google Patents

Download PDF

Info

Publication number
JP2020517668A5
JP2020517668A5 JP2019557567A JP2019557567A JP2020517668A5 JP 2020517668 A5 JP2020517668 A5 JP 2020517668A5 JP 2019557567 A JP2019557567 A JP 2019557567A JP 2019557567 A JP2019557567 A JP 2019557567A JP 2020517668 A5 JP2020517668 A5 JP 2020517668A5
Authority
JP
Japan
Prior art keywords
formula
salt
compound
alkyl
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019557567A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517668A (ja
JP7179014B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/029131 external-priority patent/WO2018200517A1/en
Publication of JP2020517668A publication Critical patent/JP2020517668A/ja
Publication of JP2020517668A5 publication Critical patent/JP2020517668A5/ja
Application granted granted Critical
Publication of JP7179014B2 publication Critical patent/JP7179014B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019557567A 2017-04-24 2018-04-24 ニラパリブの製造方法 Active JP7179014B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762489415P 2017-04-24 2017-04-24
US201762489387P 2017-04-24 2017-04-24
US62/489,387 2017-04-24
US62/489,415 2017-04-24
PCT/US2018/029131 WO2018200517A1 (en) 2017-04-24 2018-04-24 Methods of manufacturing of niraparib

Publications (3)

Publication Number Publication Date
JP2020517668A JP2020517668A (ja) 2020-06-18
JP2020517668A5 true JP2020517668A5 (enExample) 2021-06-17
JP7179014B2 JP7179014B2 (ja) 2022-11-28

Family

ID=63919973

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019557567A Active JP7179014B2 (ja) 2017-04-24 2018-04-24 ニラパリブの製造方法

Country Status (15)

Country Link
US (2) US11161834B2 (enExample)
EP (1) EP3615513B1 (enExample)
JP (1) JP7179014B2 (enExample)
KR (1) KR102582624B1 (enExample)
CN (2) CN110753684A (enExample)
AU (2) AU2018258274C1 (enExample)
CA (1) CA3060715C (enExample)
ES (1) ES2926255T3 (enExample)
IL (1) IL270068B (enExample)
MA (1) MA48475A (enExample)
MX (1) MX393879B (enExample)
SG (1) SG11201909807TA (enExample)
TW (1) TWI783993B (enExample)
WO (1) WO2018200517A1 (enExample)
ZA (1) ZA201906944B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3478286T3 (da) 2016-06-29 2024-01-29 Tesaro Inc Fremgangsmåder til behandling af ovariecancer
CN110944638A (zh) 2017-03-27 2020-03-31 特沙诺有限公司 尼拉帕尼组合物
CN110753684A (zh) 2017-04-24 2020-02-04 特沙诺有限公司 尼拉帕利的制造方法
TWI879716B (zh) 2017-05-09 2025-04-11 美商提薩羅有限公司 治療癌症的組合療法
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
BR112020006039A2 (pt) 2017-09-26 2020-10-06 Tesaro, Inc. formulações de niraparibe
SG11202002862RA (en) 2017-09-30 2020-04-29 Tesaro Inc Combination therapies for treating cancer
KR20200067164A (ko) 2017-10-06 2020-06-11 테사로, 인코포레이티드 조합 요법 및 그의 용도
US12297184B2 (en) 2018-10-03 2025-05-13 Tesaro, Inc. Niraparib salts
CN112300074B (zh) * 2019-08-02 2023-12-29 北京盈科瑞创新药物研究有限公司 一种吲唑甲酰胺类化合物及其制备方法和应用
US20250352534A1 (en) 2022-02-15 2025-11-20 Tesaro, Inc. Use of Niraparib for the Treatment of Brain Cancer
WO2024142096A1 (en) * 2022-12-29 2024-07-04 Dr. Reddy’S Laboratories Limited Process for preparation of niraparib tosylate and its intermediates
WO2025017711A1 (en) * 2023-07-20 2025-01-23 Natco Pharma Limited An improved process for the preparation of niraparib tosylate monohydrate

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
DE69841075D1 (de) 1997-04-23 2009-10-01 Kaneka Corp Deoxynukleinsäure welche ein Polypeptid mit stereoselektiver Transaminase Aktivität kodiert, sowie die Deoxynukleinsäure enthaltende Transformanden
IL136574A0 (en) 1997-12-08 2001-06-14 California Inst Of Techn A method for forming a polynucleotide of desired properties
JP4221100B2 (ja) 1999-01-13 2009-02-12 エルピーダメモリ株式会社 半導体装置
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
WO2001075767A2 (en) 2000-03-30 2001-10-11 Maxygen, Inc. In silico cross-over site selection
CA2445159C (en) 2001-04-24 2012-09-11 Massachusetts Institute Of Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
EP1403255A4 (en) 2001-06-12 2005-04-06 Sumitomo Pharma RHO KINASE INHIBITORS
CA2581179A1 (en) 2004-09-29 2006-04-06 Mitsubishi Pharma Corporation 6-(pyridinyl)-4 pyrimidone derivatives as tau protein kinase 1 inhibitors
EP2007733B1 (en) 2006-04-03 2016-05-25 MSD Italia S.r.l. Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
CA2661605A1 (en) 2006-08-31 2008-03-06 Schering Corporation Hydantoin derivatives useful as antibacterial agents
DK2805945T3 (da) * 2007-01-10 2019-07-15 Msd Italia Srl Amid-substituerede indazoler som poly(adp-ribose)polymerase- (parp) hæmmere
US7588923B2 (en) 2007-03-02 2009-09-15 Richmond Chemical Corporation Method to increase the yield and improve purification of products from transaminase reactions
PE20081889A1 (es) * 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
WO2008132139A2 (en) 2007-04-27 2008-11-06 Ucb Pharma S.A. New heterocyclic derivatives useful for the treatment of cns disorders
ES2548131T3 (es) 2008-01-08 2015-10-14 Merck Sharp & Dohme Limited Sales farmacéuticamente aceptables de 2-{4-[(3S)-piperidin-3-il]fenil}-2H-indazol-7-carboxamida
CN102405281B (zh) 2009-02-26 2015-05-13 科德克希思公司 转氨酶生物催化剂
JP2010269667A (ja) 2009-05-20 2010-12-02 Alps Electric Co Ltd 多回転角度検出装置
US8932836B2 (en) 2010-08-16 2015-01-13 Codexis, Inc. Biocatalysts and methods for the synthesis of (1R,2R)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine
AR084032A1 (es) 2010-11-30 2013-04-17 Takeda Pharmaceutical Compuesto biciclico
GEP20156351B (en) 2011-02-08 2015-08-25 Pfizer Glucagon receptor modulator
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
US9073911B2 (en) 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
US9580407B2 (en) 2012-12-07 2017-02-28 Merck Sharp & Dohme Corp. Regioselective N-2 arylation of indazoles
ES2672328T3 (es) 2012-12-07 2018-06-13 Merck Sharp & Dohme Corp. Proceso de transaminación biocatalítica
WO2016094391A1 (en) 2014-12-08 2016-06-16 Myriad Genetics, Inc. Methods and materials for predicting response to niraparib
DK3478286T3 (da) 2016-06-29 2024-01-29 Tesaro Inc Fremgangsmåder til behandling af ovariecancer
CN106496187A (zh) 2016-09-14 2017-03-15 陕西科技大学 一种制备PARP抑制剂Niraparib的合成方法
CN106432056A (zh) * 2016-09-17 2017-02-22 青岛辰达生物科技有限公司 一种尼拉帕布中间体(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的制备方法
CN106432057A (zh) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 一种制备(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的方法
CN106432055A (zh) * 2016-09-17 2017-02-22 青岛辰达生物科技有限公司 一种尼拉帕布中间体4‑(哌啶‑3‑基)苯胺的制备方法
CN110944638A (zh) 2017-03-27 2020-03-31 特沙诺有限公司 尼拉帕尼组合物
TW201842908A (zh) 2017-03-27 2018-12-16 美商提薩羅有限公司 尼拉帕尼(niraparib)調配物
CN110753684A (zh) 2017-04-24 2020-02-04 特沙诺有限公司 尼拉帕利的制造方法
TWI879716B (zh) 2017-05-09 2025-04-11 美商提薩羅有限公司 治療癌症的組合療法
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
BR112020006039A2 (pt) 2017-09-26 2020-10-06 Tesaro, Inc. formulações de niraparibe
SG11202002862RA (en) 2017-09-30 2020-04-29 Tesaro Inc Combination therapies for treating cancer
KR20200067164A (ko) 2017-10-06 2020-06-11 테사로, 인코포레이티드 조합 요법 및 그의 용도
CN111801117A (zh) 2017-12-27 2020-10-20 特沙诺有限公司 治疗癌症的方法
US20210030735A1 (en) 2018-02-05 2021-02-04 Tesaro, Inc. Pediatric niraparib formulations and pediatric treatment methods

Similar Documents

Publication Publication Date Title
JP2020517668A5 (enExample)
JP2022133462A5 (enExample)
JP2009530268A5 (enExample)
JP2018024670A5 (enExample)
JP2020536888A5 (enExample)
JP2017505801A5 (enExample)
JP2019048806A5 (enExample)
JP2010174033A5 (enExample)
JP2006507265A5 (enExample)
JP2018529650A5 (enExample)
JP2005053931A5 (enExample)
JP2020519680A (ja) 4−メトキシピロール誘導体の中間体の製造方法
TWI768716B (zh) 二芳基硫尿囊素化合物、其中間體及其製備方法
JP2017531663A5 (enExample)
JP2020535168A5 (enExample)
HRP20241103T1 (hr) 2,4-di-(skupina koja sadrži dušik)-supstituirani pirimidinski spoj i postupak pripreme i njegova upotreba
RU2012111227A (ru) Получение нейростимулирующего пиперазина
JP2018500287A5 (enExample)
FR3058834B1 (fr) Procede de fabrication d'une electrode pour accumulateur
JP2005522510A5 (enExample)
JP2020073474A5 (enExample)
JP2014520901A5 (enExample)
JP2006508093A (ja) 3−プロペニルセファロスポリンdmf溶媒和物の調製方法
JP2018535261A5 (enExample)
JP2015504917A5 (enExample)